Christopher E Rudd is a Professor of Medicine in the Department of Medicine at the Université de Montréal, and the Director of Immuno-Oncology at the Centre de Recherche Hôpital Maisonneuve-Rosemont (CR-HMR). He is also an Adjunct Professor in the Department of Medicine at McGill University and a member of the Centre of Translational Research in Cancer-McGill University. Rudd has previously held professorial positions at the Harvard Medical School, the Dana-Farber Cancer Institute (DFCI, Boston) and Imperial College London and was Professor of Molecular Immunology and the Head of the Cell Signalling Section in the Department of Pathology at Cambridge University. He also served as a member of the prestigious Board of Tutors, Harvard College, for more than a decade and was a Principal Investigator at the Cambridge Institute of Medical Research (CIMR) in Cambridge, UK. Dr. Rudd has been the recipient of a post-doctoral fellowship from the Cancer Research Institute (CRI) (New York), the recipient of the Cancer Research Institute/Benjamin Jacobson Family Investigator Award (New York), the Claudia Adams Barr Research Award (Boston), was a Scholar of the Leukemia Society of America (USA), a Principal Research Fellow (PRF) from the Wellcome Trust and presently holds a Foundation Award from the Canadian Institutes of Health Research (CIHR/IRSC). He is presently a Fellow of the Royal College of Pathologists (FRCPath) and the Academy of Medical Sciences (FMedSci) and has been an Assistant/Associate Editor of the Journal of Immunology and served on the Editorial Boards of Current Biology, Immunology, European Journal of Immunology, Seminars in Immunopathology and other journals. Rudd has served on study sections of the National Institutes of Health (USA), National Science Foundation (NSF), Cancer Research UK (CRUK) and on the Basic Immunology and Infectious Diseases Panel (BIID) of the Wellcome Trust, London. He is a member of the American Association of Immunologists (AAI), the British Society for Immunology (BSI), the Canadian Society for Immunology (CSI) and the American Society of Microbiology (ASM), was a Trustee and International Secretary of the British Society for Immunology (BSI), a Council Member of International Union of Immunological Societies (IUIS) (representing the UK) and is Head of the Immunotherapy Committee (ITH) of the IUIS. As a passionate advocate of education in immunology, he has organized two John Humphrey Advanced international courses in immunology in conjunction with the BSI, EFIS and the IUIS. Each course was highly successful, taught by 7 Professors on a wide range of advanced topics in immunology for students, clinicians and the community (>200 participants/course).
Radio and press interviews
Professor Rudd /The Naked Scientists Special Editions/13.10.06 - Stopping HIV Spread - Naked Scientists Specials.mp3; https://www.cam.ac.uk/research/ news/new-target-to-fight-hiv-infection-identifiedmedicalxpress.com/ pdf29983 9629.pdf; www.cambridgenetwork.co.uk/news/new-target-to-fight-hivinfection; globalindianewsline.com /2013/10/03/scientists-discover-mutant https:// www.thenakedscientists.com/HTML/specials/show/20131006/
Professor Rudd Game changing cancer cure_-Naked Scientists Special.mp3
Le Devoir 'Percée majeure pour le traitement du cancer', recent work in cancer immunotherapy, 19/7/17; 4)
CBC radio: Home Run, Montreal, 25/7/17
https://ciusss-estmtl.gouv.qc.ca /actualite/ page/2/
La Press, 30/8/17 Recent advances in cancer therapy
30/8/17 Un chercheur d'ici sur la bonne piste pour vaincre plus de cancers | LeBel Âge
7/10/2018 Les annees lumiere (Radio Canada, CBC), Le prix Nobel de Medicine 2018: Un mecanisme cellulaire utilise contre le cancer.
Christopher E Rudd, Ph.D., D.Sc., FRCPath, FMedSci
Professor of Medicine, Department of Medicine, Department of Microbiology, Infection and Immunology, Universite de Montreal , Prinicipal Investigator, Centre de Recherche Hôpital Maisonneuve-Rosemont (CR-HMR), Director, Cell Signalling in Immunotherapy Unit, Director of Immunology and Cell Therapy (CR-HMR), Head of Immuno-Oncology (CR-HMR), Laboratoires Antoine Turmel, Room 305, Polyclinique de l'Hôpital Maisonneuve-Rosemont, 5345, Boulevard de l'Assomption, Montreal, QC, Canada H1T 4B3Tel: 1-514- 252 3400, ext. 5878; E-mail: Christopher.firstname.lastname@example.org, ,
Professeur de médecine, Département de médecine, Département de microbiologie, infectiologie et immunologie, Université de Montréal, Chercheur principal, Centre de recherche de l'Hôpital Maisonneuve-Rosemont (CR-HMR), directeur de l'unité de signalisation cellulaire en immunothérapie, chef de l'axe immunologie et de la thérapie cellulaire (CR-HMR), chef de l'oncologie (CR-HMR), Laboratoires Antoine Turmel, Room 305, Polyclinique de l'Hôpital Maisonneuve-Rosemont, 5345, Boulevard de l'Assomption, Montreal, QC, Canada H1T 4B3Tel: 1-514- 252 3400, ext. 5878; E-mail: Christopher.email@example.com, ,